<DOC>
	<DOCNO>NCT00982865</DOCNO>
	<brief_summary>This first man trial primary objective determination Maximum Tolerated dose ( MTD ) dose-limiting toxicity ( DLT ) several regimen MEK inhibitor MSC1936369B administer orally day , subject malignant solid tumor see safe treatment MSC1936369B .</brief_summary>
	<brief_title>Trial MSC1936369B Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Pathologicallyconfirmed solid tumor locally advance metastatic , either refractory standard therapy disease effective standard therapy available . In regimen 3 , regimen 2 foodeffect , BID cohorts , tumor type restrict melanoma . Age great equal ( &gt; = ) 18 year Has read understands informed consent form willing able give inform consent . Fully understand requirement trial willing comply trial visit assessment Bone marrow impairment evidence Haemoglobin le ( &lt; ) 9.0 gram per deciliter ( g/dL ) , Neutrophil count &lt; 1.0 x 10^9/Liter , platelet &lt; 100 x 10^9/Liter Renal impairment evidence serum creatinine &gt; 1.5 x upper limit normal ( ULN ) , and/or calculate creatinine clearance &lt; 60 milliliter per minute ( mL/min ) Liver function abnormality define total bilirubin &gt; 1.5 x ULN , aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) &gt; 2.5 x ULN , subject liver involvement AST/ALT &gt; 5 x ULN INR &gt; 1.5 x ULN Serum calcium &gt; 1 x ULN History central nervous system ( CNS ) metastases , unless subject previously treat CNS metastasis , stable computer tomography ( CT ) scan without evidence cerebral oedema , requirement corticosteroids anticonvulsant History difficulty swallowing , malabsorption chronic gastrointestinal disease condition may hamper compliance and/or absorption test product Eastern Cooperative Oncology Group Performance status ( ECOG PS ) great ( &gt; ) 1 Known human immunodeficiency virus ( HIV ) positivity , active hepatitis C , active hepatitis B</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MEK inhibitor</keyword>
	<keyword>Cancer</keyword>
	<keyword>Solid tumor</keyword>
</DOC>